Basic Trial Information
Trial Description
     Summary
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

Peripheral T cell lymphomas comprise 10-15% of all malignant lymphomas. The prognosis is significantly worse than that of aggressive B cell lymphomas. The prospects of elderly patients are especially poor, with an estimated disease free survival of only 25% after three years. Previous phase II trials have demonstrated a significant activity of the monoclonal anti CD52 antibody alemtuzumab in primary and relapsed T cell lymphoma. The investigators thus propose to investigate the value of adjuvant alemtuzumab in combination with dose dense CHOP-14 in patients with previously untreated peripheral T cell lymphoma.

Eligibility Criteria

Inclusion Criteria:

• all risk groups of peripheral T cell lymphoma

• performance status ECOG 0-2

• written consent

• measurable disease

Exclusion Criteria:

• stage I N without bulky disease

• already initiated treatment

• serious accompanying disorder or impaired organ function

• bone marrow involvement >25%

• HIV positivity

• leukemic manifestation of lymphoma

• simultaneous participation in another trial

• platelets < 100 000/ mm, leukocytes < 2500 /mm

Trial Contact Information

Trial Lead Organizations/Sponsors

Universitaetsklinikum Goettingen

L. Trumper

Principal Investigator

Lorenz H Trümper, MD		Ph: +49 551 398535 Ext.8535
		Email: lorenz.truemper@med.uni-goettingen.de

Germany
	Göttingen
	Universitaetsklinikum Goettingen

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00725231
Information obtained from ClinicalTrials.gov on May 06, 2012

Back to Top